We transform critical care medicine by developing innovative and effective therapies based on alkaline phosphatase (RESCAP®). We are guided by our core values of loyalty towards relationships, accuracy, and high scientific commitment, which underpin everything we do.
Our goal is to create a positive impact on the world by bringing new hope to patients and their families through safe, effective, and accessible treatments that improve outcomes and enhance quality of life.
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with
July 1-2024. Alloksys anticipates that a treatment with RESCAP® reduces the immediate complications resulting from the kidney transplantation procedure and improves the long-term graft survival.
Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today announced
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
After approval was obtained in October 2018, the kidney transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with
July 1-2024. Alloksys anticipates that a treatment with RESCAP® reduces the immediate complications resulting from the kidney transplantation procedure and improves the long-term graft survival.
Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today announced
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
